USV Ltd vs Eli Lilly: Copy of Decision Rejecting Lilly Application

/ By / Uncategorized

I’m trying to lay my hands on the patent office pre grant decision in USV vs Eli Lilly, where USV successfully challenged Eli Lilly’s application for Forteo, an osteoporosis drug. I had blogged on it earlier here. If any of you have a copy of the decision or know someone at USV Ltd that can give us a copy of the decision, please let me know at . I promised to review this decision in my earlier post–but have been […]

USV Ltd vs Eli Lilly: Copy of Decision Rejecting Lilly Application Read More »

SpicyIP Petition: Request to make Indian Patent Information Public

/ By / Patent

I’m sure that a number of you have been frustrated with the lack of a good Indian patent database. We’ve therefore created a online petition addressed to the Prime Minister, Dr Manmohan Singh, highlighting this lacuna and requesting his intervention. We urge all those concerned with this dismal state of affairs to voice your support by signing this petition (it will be helpful if you also state your affiliation in the signature, although this is not mandatory). We hope to

SpicyIP Petition: Request to make Indian Patent Information Public Read More »

Golly, Google!, says T-series

/ By / Copyright

Super Cassettes Industries Limited (SCIL), which owns the T-Series label, has won an interim restraining order against YouTube and its parent company Google in a copyright infringement case. The Delhi High Court passed a brief interim order restraining Youtube and Google from reproducing, adapting, distributing, communicating, transmitting, disseminating or displaying on their websites or otherwise infringing … any audio-visual works in which the plaintiff [SCIL] owns exclusive, valid and subsisting copyright. SCIL alleged that YouTube and Google have made available

Golly, Google!, says T-series Read More »

SpicyIP Events

/ By / Others

1. Trademarks and Geographical Indications A round table on Striking a Balance Between Trademarks and Geographical Indications: The Italian Perspective is scheduled for Nov 21, 2007 (2:30pm)and might be of interest to our readers in Italy (The round table will be presented in Italian.) According to the INTA Website, the round table will focus on the different degrees of protection offered by trademarks and geographical indications, aimed at opening a debate on whether there exist any shared principles capable of

SpicyIP Events Read More »

Spicyip Tidbits

/ By / Uncategorized

1. IndiaFalls Five Places in the Global Economic Forum India has fallen five notches in the latest annual rankings of the Global Competitiveness Report released by the World Economic Forum. India was placed 48 in the list of 131 economies covered under the Global Competitiveness Index (GCI) which tracks twelve parameters to come out with the rankings. Among the top emerging markets, India is second this year behind China. The quality of the business environment in India has improved tangibly

Spicyip Tidbits Read More »

Takeda vs Alphapharm: Implications for Section 3(d)

/ By / Patent

This comes a little late in the day, but I finally managed to read the CAFC ruling in Takeda Chem. Indus. et al. v. Alphapharm et al (No. 2006-1329 (Fed. Cir. 2007)). Should be of particular interest to India, given that this involves Actos, an anti-diabetic drug by Takeda Chem Industries, Japan’s leading pharma company. Bloomberg recently reported that “Actos” overtook GlaxoSmithKline Plc’s “Avandia” as the world’s top-selling diabetes medicine after the Glaxo drug was linked in a May 21

Takeda vs Alphapharm: Implications for Section 3(d) Read More »

Indian Ingenuity in the Pharma industry – not just generics

/ By / Uncategorized

Eli Lilly and Glenmark announced last week a deal in which Lilly will license from Glenmark the rights to a new set of molecules (a portfolio of TRPV1 antagonist molecules, including a clinical compound, GRC 6211.) The world has for some time been well aware (and impressed) with the performance of India’s top ‘generic’ companies. In an interesting example of taking a generic IP Strategy to the next level, Lupin entered into two recent IP portfolio sales to Servier earlier

Indian Ingenuity in the Pharma industry – not just generics Read More »

SpicyIP Events

/ By / Uncategorized

1. Symposium on Intellectual Property and Life Sciences Regulation organized by the World Intellectual Property Organization in cooperation with the Stockholm Network: November 16, 2007 Rapid evolution in the life sciences – in biomedical research, in agricultural biotechnology – has spurred two related trends, of relevance to policymakers: sharp increases in patenting activity, and strong public interest in ensuring appropriately rigorous regulation of new biotechnologies. And the interaction between intellectual property protection and regulatory mechanisms in the life sciences has

SpicyIP Events Read More »

SpicyIP Tidbits

/ By / Uncategorized

1. Bajaj-TVS spat revs up again India’s second largest two-wheeler manufacturer Bajaj Auto Limited (BAL) on Saturday has asserted that the company is going to take necessary steps so that its intellectual property rights (IPR) remain protected. BAL is currently involved with TVS Motor Co over a patent issue involving the BAL’s Digital Twin Spark-ignition (DTS-i) which it claims TVS has copied in its new 125cc bike Flame. Flame is expected to hit the market by next month. Refuting Bajaj’s

SpicyIP Tidbits Read More »

The Biological Diversity Act

/ By / Biological Diversity

How many of you have heard of the Biological Diversity Act, 2002? I had heard about the Act long ago but somehow never got down to actually trying to understand it and when I did get down to it while researching for this post I was quite stunned with both, the importance of this Act and the seemingly muted discussions of such an important piece of legislation in the mainstream press. Unlike The Patent Act which is considered the ‘sexier’

The Biological Diversity Act Read More »

Scroll to Top